CorMedix Q2 net loss widens to $11.3M; DefenCath NDA PDUFA date Nov 15, 2023

CorMedix Inc.

2023-Q2 EPS reported -$0.49

Net loss of $11.3M ($0.25 per share) vs $7.6M loss in Q2 2022, driven by increased R&D and SG&A.
Cash and short-term investments $52.4M at June 30; after July equity offering pro forma cash ~$95M.
DefenCath NDA accepted with PDUFA target date of November 15, 2023; CMS set NTAP up to $17,111 if approved.
Operating expenses increased 43% to $11.8M; R&D up 49% to $4.8M; SG&A up 39% to $7.0M.
Strategic initiative with Boston Medical Center to assess CRBSI incidence and health disparities.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CorMedix Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 8, 2023, CorMedix Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

CorMedix Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-064241

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.